Mazdutide

Dual glucagon receptor / GLP-1 receptor agonist peptide

Obesitytype 2 diabetes

Mazdutide

Evidence levelMixed evidence

Human evidenceSee evidence

Regulatory statusApproved in China

What you need to know in 20 seconds

What is it?	Dual glucagon receptor / GLP-1 receptor agonist peptide
Research focus	Obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea
Human evidence	Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes.
Regulatory status	First approved in China in June 2025 for chronic weight management in qualifying adults; later approved there for glycaemic control in type 2 diabetes. Not a globally authorised medicine.
Main limitations	Global regulatory approval, long-term outcomes across diverse populations, and equivalence of non-authorised products are not established.
Safety	GI adverse events are the main recurring trial signal; longer-term outcomes and use outside studied populations require caution.

Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes.

What the evidence actually supports

✓Strong evidence in studied population; do not globalise regulatory status.

What is not established / key limitations

×No direct completed head-to-head obesity-outcome trial against current high-dose semaglutide/tirzepatide in the retrieved evidence.

Selected study & evidence records

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1)

2025 · Randomized, double-blind, placebo-controlled trial · n=610

At week 48: -11.00% (4 mg), -14.01% (6 mg), +0.30% placebo; ≥15% loss in 35.7%, 49.5%, 2.0%.

Study detail → Primary source ↗

GLORY-2: 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity

2026 · Randomized, double-blind, placebo-controlled trial · n=462

Phase 3 high-dose study demonstrated clinically meaningful weight reduction; full outcome-by-outcome extraction retained in source review queue.

Study detail → Primary source ↗

Safety and unknowns

GI adverse events are the main recurring trial signal; longer-term outcomes and use outside studied populations require caution.

Gastrointestinal adverse events including diarrhoea, nausea and vomiting are common in trials; longer-term and broader-population safety continues to accumulate.

Technical details

Mechanism / biologyCo-agonism at glucagon and GLP-1 receptors aims to combine appetite/glycaemic effects with glucagon-linked energy expenditure and hepatic metabolic effects.

Route / formulation boundaryClinical evidence concerns regulated trial/authorised subcutaneous formulations. Research-market material cannot be assumed equivalent.

Identity / data-quality noteClearly distinguish China authorisation from status in UK/EU/US.

Dosing evidence statusPhase 3 human dosing verified. GLORY-1 studied 4 mg and 6 mg once weekly; GLORY-2 studied 9 mg once weekly. See dosing records.

Identifiers & alternate namesIBI362 · LY3305677 · Xinermei